Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-05-19
1997-08-12
Davis, Zinna Northington
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
548505, C07D20904, A61K 3140
Patent
active
056566557
ABSTRACT:
A method of inhibiting cell proliferation in a patient suffering from such disorder comprising the administration to the patient of a pharmaceutically effective amount of a pharmaceutical composition containing, in admixture with a pharmaceutically acceptable carrier, a compound, or a pharmaceutically acceptable salt thereof, of the formula ##STR1## wherein the radicals are defined in the specification.
REFERENCES:
patent: 3149148 (1964-09-01), Kladko et al.
patent: 3157663 (1964-11-01), Bencze
patent: 3196158 (1965-07-01), Bencze
patent: 3337565 (1967-08-01), Bencze et al.
patent: 3337568 (1967-08-01), Bencze et al.
patent: 3381006 (1968-04-01), Suh
patent: 4600712 (1986-07-01), Haken et al.
patent: 4678793 (1987-07-01), Klaus et al.
patent: 4769384 (1988-09-01), Kise et al.
patent: 4826984 (1989-05-01), Berlin et al.
Horner et al., Liebigs Ann. Chem. vol. 6, 1183-210 (1982).
Robinson et al., Tetrahedron, 45 (13), 4103-4112 (1989).
Makosza et al., Chem. Abstracts, 105(25) 225979N (1986).
Fuentes et al., Chem. Abstracts, 89(17), 146731Y (1978).
Yukhnovski et al., Chem. Abstracts, 77(13), 87206H (1971).
Buu-Hoi et al., J. of the Chemical Society, (C), 2069-70 (1969).
Fuentes et al., Anales de Quimica, 73, 1359-1362 (1977).
Magarian et al, J. Pharm. Science, vol. 58(9), pp. 1166-1167, 1969.
Birev et al., Chemical Abstract vol. 88, No. 5, Abstract 36958z, Jan. 30, 1978, p. 436.
Colau et al., Chemical Abstract, vol. 92, No. 5, Abstract 41526u, Feb. 4, 1930, p. 744.
Gazit Aviv
Gilon Chaim
Levitzki Alexander
Persons Paul E.
Spada Alfred P.
Davis Zinna Northington
Rhone-Poulenc Rorer Pharmaceuticals Inc.
LandOfFree
Styryl-substituted heteroaryl compounds which inhibit EGF recept does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Styryl-substituted heteroaryl compounds which inhibit EGF recept, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Styryl-substituted heteroaryl compounds which inhibit EGF recept will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-160968